Ulcerative colitis and Hyperbilirubinaemia aggravated

Summary:

Hyperbilirubinaemia aggravated is found among people with Ulcerative colitis, especially for people who are male, 40-49 old.

The study analyzes which people have Hyperbilirubinaemia aggravated with Ulcerative colitis. It is created by eHealthMe based on reports of 12 people who have Ulcerative colitis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 25, 2022

12 people who have Ulcerative Colitis and Hyperbilirubinaemia Aggravated are studied.


What is Ulcerative colitis?

Ulcerative colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine) is found to be associated with 2,339 drugs and 1,770 conditions by eHealthMe.

What is Hyperbilirubinaemia aggravated?

Hyperbilirubinaemia aggravated (excess of bilirubin in the blood) is found to be associated with 462 drugs and 175 conditions by eHealthMe.

Number of Hyperbilirubinaemia aggravated in Ulcerative colitis reports submitted per year:

Would you have Hyperbilirubinaemia aggravated when you have Ulcerative colitis?

Gender of people who have Ulcerative Colitis and experienced Hyperbilirubinaemia Aggravated *:

  • female: 18.18 %
  • male: 81.82 %

Age of people who have Ulcerative Colitis and experienced Hyperbilirubinaemia Aggravated *:

  • 0-1: 0.0 %
  • 2-9: 16.67 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 16.67 %
  • 40-49: 50.0 %
  • 50-59: 16.67 %
  • 60+: 0.0 %

Common co-existing conditions for these people *:

  1. Hiv Infection: 5 people, 41.67%
  2. Giardiasis (intestinal infection caused by the parasite giardia lamblia): 4 people, 33.33%
  3. Canker Sores (painful, open sore in the mouth): 4 people, 33.33%
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 16.67%
  5. Hypotension (abnormally low blood pressure): 2 people, 16.67%
  6. Colitis (inflammation of colon): 2 people, 16.67%
  7. Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 2 people, 16.67%
  8. Type 2 Diabetes: 1 person, 8.33%
  9. Bone Marrow Conditioning Regimen: 1 person, 8.33%
  10. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 8.33%

Common drugs taken by these people *:

  1. Norvir: 5 people, 41.67%
  2. Pentasa: 5 people, 41.67%
  3. Pentacarinat: 5 people, 41.67%
  4. Isentress: 5 people, 41.67%
  5. Reyataz: 5 people, 41.67%
  6. Azathioprine: 4 people, 33.33%
  7. Fungizone: 4 people, 33.33%
  8. Remicade: 3 people, 25.00%
  9. Imodium: 3 people, 25.00%
  10. Truvada: 3 people, 25.00%

Common symptoms for these people *:

  1. Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 6 people, 50.00%
  2. Diarrhea: 6 people, 50.00%
  3. Nausea (feeling of having an urge to vomit): 6 people, 50.00%
  4. Skin Exfoliation (removal of the oldest dead skin cells): 5 people, 41.67%
  5. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 5 people, 41.67%
  6. Rashes (redness): 5 people, 41.67%
  7. Itching: 5 people, 41.67%
  8. Seborrhoeic Dermatitis (a common, inflammatory skin condition that causes flaky, white to yellowish scales to form on oily areas such as the scalp): 5 people, 41.67%
  9. Enanthema (rash formed inside the body): 5 people, 41.67%
  10. Toxic Skin Eruption (skin breakdown due to toxic substance): 5 people, 41.67%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Hyperbilirubinaemia aggravated?

Check whether Hyperbilirubinaemia aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Hyperbilirubinaemia aggravated:

Common drugs associated with Hyperbilirubinaemia aggravated:

All the drugs that are associated with Hyperbilirubinaemia aggravated:

Common conditions associated with Hyperbilirubinaemia aggravated:

All the conditions that are associated with Hyperbilirubinaemia aggravated:

How the study uses the data?

The study is based on Hyperbilirubinaemia aggravated and Ulcerative colitis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: